SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Vara Network is a substrate-based future proof smart contract platform that is fast, scalable, and makes it simple to create and deploy next-generation Web3.0 dApps Vara is the first standalone network in the Gear Protocol  Gear is a next-gen cloud infrastructure platform providing most intuitive and frictionless environment for web2 and web3 developers to build complex infrastructure solutions and disruptive dApps for any ecosystem  What makes your project unique? Vara is built upon three core concepts: The actor model, and persistent memory — two widely adopted primitives from massive computation and microservices architecture spaces  Wasm — a WebAssembly-based virtual machine that runs on all modern browsers. Proven to be faster than any alternative web2 virtual machines  Vara was created to serve as a wasm-native hub for innovative protocols that leverage parallel execution and asynchronous programming to deliver leading decentralized products in any segment  History of your project. Gear Protocol and the Vara Network were originally created by Nikolay Volf, one of the core developers of Polkadot. In 2021, he embarked on building an advanced layer 1 smart contract platform using Substrate, Polkadot's custom framework. His vision included creating a platform that enables fast and efficient execution of robust, feature-rich dApps while in a seamless development environment similar to that of Web 2.0 development. He did this by  harnessing the power of innovative technologies like Wasm, the Actor Model, and Persistent Memory. These technologies significantly enhance smart contract development and provide a seamless end-user experience and provide the foundation for the development of Vara Network.  1. Q2 2021 - Pre-Seed Round: In the second quarter of 2021, the Protocol secured its initial funding through a pre-seed round. This likely involved seeking investment from early-stage investors or venture capitalists to kickstart the development of the project.  2. Q4 2021 - Seed Round: In December 2021 raised $12 Million in Venture Round. Private investment round led by Blockchange Venture. In addition to Blockchange, other top venture capital funds participated in this round, including Three  Arrows Capital, Lemniscap, Distributed Global, LAO, Mechanism Capital, Bitscale, Spartan Group LLC, HashKey, DI Ventures, Elysium Venture Capital, Signum Capital and P2P Economy lead by Konstantin Lomashuk, along with a number of top executives of Web3 Foundation and Parity Technologies. Dr. Gavin Wood, Founder and ex-CEO of Parity Technologies and one of the key individual investors participating in this round.  3. 2022 - Intensive Scaling and Development, First Test Integrations: Throughout the year 2022, Vara was focused on two primary activities. First, the engagement in an extensive outreach process to build up the team. Second, the project advanced its technical development efforts and started working on integrating their technology with various test environments to ensure its functionality and viability.  4. Q4 2022 - Testnet Launch.   5. Q1 2023 - PoA Launch: In the first quarter of 2023, Vara achieved launch of its Proof of Authority (PoA) consensus network, which is a chain candidate for mainnet.  Current Status of Vara:  Presently, the project boasts a talented and diverse decentralized workforce, consisting of dozens of engineers and other community members  to drive the project's success.  One of the remarkable aspects of Vara is its substantial pipeline of initiatives with over 40 projects.  What’s next for your project? Current projects being researched and developed by the community:  - Intensive testing and improvement of the actor model features in the blockchain space  - Launch of the key stack of dApps in our parallel and asynchronous environment   - Development of innovative infrastructure solutions (e.g offchain zk actors including machine learning) independently and together with the segment leaders  What can your token be used for? VARA tokens maintain core utility features required for the network to operate: transaction fees staking and network security governance other: gas pools for gas reservation  Contributors to the Gear protocol are exploring the mechanics of how to distribute a portion of block rewards directly toward dApp developers

Vara Network

Vara Network is experiencing heightened social sentiment and trading activity as investors react to its recent availability on major exchanges and the deployment of new DeFi infrastructure like the Tokenator no-code launcher. While the community is actively debating the project's potential for a long-term breakout driven by institutional partnerships and RWA utility, many participants remain cautious, closely monitoring ongoing token supply unlocks and price volatility.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining momentum as a critical infrastructure provider in the DeFi space, fueled by its role in bringing institutional-grade data and U.S. government macroeconomic indicators onto the blockchain. The community is focused on the project's real-world utility, its revenue-sharing model through token buybacks, and its growing importance within the Real World Asset sector.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy (VLO) is experiencing high volatility as investors weigh the impact of shifting geopolitical tensions and potential supply disruptions against the company's refining fundamentals. The stock remains a focal point for the community due to its sensitivity to crack spreads and policy-driven energy transitions, with traders closely monitoring the intersection of oil price volatility and institutional positioning.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is gaining attention as investors navigate its strategic shift toward sports-focused streaming, highlighted by a high-profile sports bundle initiative alongside industry peers. Meanwhile, community discussions are sharply divided, balancing interest in the stock's media and advertising performance with intense debate over the network's shifting political positioning.

Vermilion Energy, Inc. engages in the acquisition, exploration, development, and production of oil and natural gas. It operates through the following geographical segments: Canada, United States of America, France, Netherlands, Germany, Ireland, Australia, and Corporate. The company was founded by Lorenzo Donadeo and Claudio A. Ghersinich in 1994 and is headquartered in Calgary, Canada.

Vermilion Energy Inc

Vermilion Energy is capturing investor attention as a direct play on European natural gas prices, with community members actively discussing its strategic asset portfolio and consistent share buyback programs. Sentiment remains divided between those bullish on its free cash flow potential and those frustrated by its price correlation with broader energy macro trends and historical hedge performance.

EOG Resources, Inc. engages in the exploration, development, production and marketing of crude oil and natural gas. It operates through the United States, Trinidad, and Other International geographical segments. The Other International segment includes China and Canada operations. The company was founded in 1985 and is headquartered in Houston, TX.

EOG Resources, Inc.

EOG Resources is attracting significant investor attention as analysts highlight its strong production efficiencies, disciplined capital allocation, and role as a top-tier operator in major basins like the Permian. The community is actively discussing the company's potential to capitalize on long-term energy demand and rising natural gas exposure, with many monitoring its technical levels as it navigates a volatile sector.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

Molina Healthcare is trending following a significant post-earnings plunge driven by an unexpected quarterly loss and a major downward revision to full-year earnings guidance. Investors are actively debating whether this sell-off represents a generational buying opportunity for the value-focused stock or a sign of deeper sector-wide instability regarding Medicare and Medicaid cost trends.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as investors await critical updates following a recent Type C meeting with the FDA, with community sentiment heavily focused on potential accelerated approval for its ALS treatment, CNM-Au8. Discussion is driven by intense speculation regarding upcoming biomarker analysis results and whether the company will secure an NDA filing by the end of the year.

Halliburton Co. engages in the provision of products and services to the energy industry. It operates through the Completion and Production, and Drilling and Evaluation segments. The Completion and Production segment focuses on cementing, stimulation, specialty chemicals, intervention, pressure control, artificial lift, and completion products and services. The Drilling and Evaluation segment provides field and reservoir modeling, drilling, fluids, evaluation, and wellbore placement solutions that enable customers to model, measure, drill, and optimize well construction activities. The company was founded by Erle P. Halliburton in 1919 and is headquartered in Houston, TX.

Halliburton Co.

Halliburton is trending as traders closely watch a surge in oil services activity following geopolitical developments in Venezuela, with the stock drawing attention for its potential role in restoring regional energy infrastructure. The community is actively discussing its long-term recovery prospects, comparing the company's valuation to peers like Schlumberger, and debating the merits of recent institutional call volume against broader sector volatility.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is experiencing high volatility as investors track a surge in lithium spot prices and speculate on potential production updates and phase expansion timelines. The stock remains a focal point for community debate, with bulls citing potential supply deficits and technical breakouts while bears emphasize liquidity concerns, regulatory hurdles, and recurring short-selling reports.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model Hoth Therapeutics Reports Positive Female Preclinical...

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PR Newswire...

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND...

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy...

<ul class="summary-bullets"><li>GDNF outperformed semaglutide, the active ingredient in Wegovy and Ozempic, across several key measures, Hoth said.</li><li>The 12-week study showed that female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, whereas semaglutide showed no meaningful effect.</li><li>The company said GDNF reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease.</li></ul>Hoth Therapeutics (HOTH), on Tuesday, announced preclinical results from a Veterans Administration-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disease (MASLD).The company stated that in a head-to-head comparison, GDNF outperformed semaglutide, the active ingredient in weight-loss drugs such as Wegovy and Ozempic, across several key measures, including weight control, glucose tolerance, liver weight reduction, and adipose tissue control.<a href="https://stocktwits.com/symbol/HOTH">HOTH shares</a> were up over 5% in pre-market trading but reversed gains after the opening bell, trading 6% lower.<h2 class="st-heading-2">What Did The 12-Week Study Show?</h2>During the 12-week study, female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, eventually entering a stabilization phase, whereas semaglutide showed no meaningful effect. Researchers noted that higher doses or longer durations could amplify GDNF’s effects.GDNF also normalized fasting glucose levels and improved responses to glucose challenges. Additionally, the therapy reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease, a common issue with obesity.“These results are a monumental step forward for Hoth and the fight against obesity. GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies,” said Robb Knie, CEO of Hoth Therapeutics.<h2 class="st-heading-2">What’s Next?</h2>Hoth plans additional studies on liver pathology, lipid content, and gene and protein expression to better understand GDNF’s mechanism, with clinical trials targeted for 2027.Weight-loss drugs have become a central focus for the pharmaceutical industry, driving revenue growth for leaders like Eli Lilly and Novo Nordisk as other companies race to enter the booming market.The segment has been under regulatory spotlight in the aftermath of Hims &amp; Hers launching a compounded version of Wegovy last week, which the company has since withdrawn following legal notices from NOVO and the U.S. Food and Drug Administration.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment turned ‘bullish’ from ‘neutral’ a day earlier, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/HOTH_jpg_40deb046fb.webp" alt="HOTH.jpg">One user called for patience amid the intraday decline.<stembedurl>https://stocktwits.com/Tom678/message/644546402</stembedurl>HOTH shares are down around 21% so far this year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/why-did-azi-stock-reverse-gains-in-premarket/cZbUIHFR4Yy">AZI Stock Reverses Early Gains To Slump 30% In Pre-Market – What Happened?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Equity

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PR Newswire NEW YORK, Feb. 5, 2026 NEW...

Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half

Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, fewer side effects, and early lasting benefits in cancer patients on EGFR...

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients Hoth Therapeutics Delivers 100% Clinical Response...

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position Hoth Therapeutics Secures Major International Patent Milestone for...

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation Hoth Therapeutics Reaches Key EU Regulatory Inflection Point...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

HOTH
Hoth Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest HOTH News

HOTHHoth Therapeutics Inc